DOI QR코드

DOI QR Code

Compound K, a Metabolite of Ginsenoside Rb1, Inhibits Passive Cutaneous Anaphylaxis Reaction in Mice

  • Bae, Eun-Ah (Deparlment of Life and Pharmaceutical Sciences, Kyung Hee University) ;
  • Trinh, Hien Trung (Deparlment of Life and Pharmaceutical Sciences, Kyung Hee University) ;
  • Yoon, Hae-Kyung (Department of Food and Nutrition, Kyung Won University) ;
  • Kim, Dong-Hyun (Deparlment of Life and Pharmaceutical Sciences, Kyung Hee University)
  • Published : 2009.06.30

Abstract

To understand the anti-allergic mechanism of compound K, which is a metabolite of ginsenoside Rb1, a main constituent of the root of Panax ginseng C.A. Meyer (family Araliaceae), its inhibitory effect against IgE-antigen complex IAC)-induced passive cutaneous anaphylaxis (PCA) reaction in mice and mRNA and protein expressions of allergic cytokines in lAC-stimulated RBL-2H3 cells were investigated. Orally administered ginsenoside Rb1 more potently inhibited PCA reaction when administered at 5 h prior to the lAC treatment than when administered at I h before. However, compound K orally administered 1 h before lAC treatment showed a more potent anti-PCA reaction effect than when treated at 5 h before. Orally administered ginsenoside Rb1 more potently inhibited PCA reaction induced by lAC in mice than intraperitoneally treated one, apart from orally administered its metabolite, compound K, which was more potent than the orally administered one. The compound K, a metabolite of ginsenoside Rb1, inhibited mRNA and protein expressions of IL-4 and TNF-${\alpha}$ and the activation of their transcription factor NF-$\kappa$B and MAPK in lAC-stimulated RBL-2H3 cells. These findings suggest that orally administered ginsenoside Rb1 may be dependent on its metabolism by intestinal microflora in the intestine and the compound K may improve allergic diseases by the inhibition of IL-4 and TNF-${\alpha}$ expresseion.

Keywords

References

  1. Stevens RL, Austen KF. Recent advances in the cellular and molecular biology of mast cells. Immunol Today. 10: 381-386 (1989) https://doi.org/10.1016/0167-5699(89)90272-7
  2. Plaut M, Pierce JH, Whatson C, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to cross-linkage of Fe epsilon RI or to calcium ionophore. Nature, 339: 64-67 (1989) https://doi.org/10.1038/339064a0
  3. Bruhns P,Fremont S, Daeron M. Regulation of allergy by Fe receptors. Curr Opin Immunol. 17: 662-669 (2005) https://doi.org/10.1016/j.coi.2005.09.012
  4. Nicoloff B. The cytokine network in psoriasis. J Arch Dermatol. 127: 871-884 (1991) https://doi.org/10.1001/archderm.127.6.871
  5. Mitre E, Nutman TB. Basophils, basophilia and helminth infections. Chem Immunol Allergy. 90: 141-156 (2006) https://doi.org/10.1159/000088886
  6. Wuthrich B. Epidemiology of the allergic diseases: are they really on the increase? Int Arch Allergy Appl Immunol. 90 (suppl. 1), 3-10 (1989) https://doi.org/10.1159/000235067
  7. Schafer-Korting M, Schmid MH, Korting HC. Topical glucocorticoids with improvedrisk-benefit ratio. Rationale of a new concept. Drug Safety. 14: 375-385 (1996) https://doi.org/10.2165/00002018-199614060-00003
  8. Sakuma S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, Amaya T, Goto T. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol. 1: 1219-1226 (2001) https://doi.org/10.1016/S1567-5769(01)00059-5
  9. Simons FE. The antiallergic effects of antihistamines (Hlreceptor antagonists). J Allergy C1in Immunol. 90: 705-715 (1992) https://doi.org/10.1016/0091-6749(92)90156-V
  10. Bielory L. Complementary and alternative interventions in asthma, allergy, and immunology. Ann Allergy Asthma Immunol. 93 (Suppl 1): S45-54 (2004) https://doi.org/10.1016/S1081-1206(10)61486-X
  11. Yang SH, Hong CY, Yu CL. Decreased serum IgE level, decreased IFN-gamma and IL-5 but increased IL-I0 production, and suppressed cyclooxygenase 2 mRNAexpression in patientswith perennial allergic rhinitis after treatmentwith a new mixed formula of Chinese herbs. Int Immunopharmacol. 1: 1173-1182 (2001) https://doi.org/10.1016/S1567-5769(01)00051-0
  12. Tanaka N, Tanaka O, Shibata S. Chemicalstudieson the oriental plant drugs. XXVIII. Saponins and sapogenins of ginseng; Stereochemistry of sapogenin of ginsenoside Rb1, Rb2 and Rc. Chem Pharm Bull. 20: 1212-1216 (1972) https://doi.org/10.1248/cpb.20.1212
  13. Shibata S, Fujita M, Itokawa H, Tanakao, Ishii T. Panaxadiol, a sapongenin of ginseng roots (1). Chem Pharm Bull. 11: 759-764 (1963) https://doi.org/10.1248/cpb.11.759
  14. Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ. Saponinadjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol. 148: 1519-1525 (1992)
  15. Mochizuki M, YooCY, Matsuzawa K, Sato K, Saiki I, Tonooka S, Samukawa K, Azuma J. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside Rb2, 20(R)-and 20(S)-ginsenoside Rg3, of Red ginseng. Biol Pharm Bull. 18: 1197-1202 (1995) https://doi.org/10.1248/bpb.18.1197
  16. Wakabayashi C, HasegawaH, MurataJ, Saiki I. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol Res. 9: 411-417 (1998)
  17. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compoundK in rat plasma after oral administration of ginsenoside RbI from Panax ginseng. J Pharm Pharmacol. 50: 1155-1160 (1988) https://doi.org/10.1111/j.2042-7158.1998.tb03327.x
  18. Hasegawa H, Sung JR, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing Ginseng saponis. Planta Med. 63: 436-440 (1997) https://doi.org/10.1055/s-2006-957729
  19. Akao T, Kanaoka M, Kobashi K. Appearance of compound K, a major metabolite of ginsenoside Rbl by intestinal bacteria, in rat plasma after oral administration-measurement of compound K by enzyme immunoassay. BioI Pharm Bull. 21: 245-249 (1998) https://doi.org/10.1248/bpb.21.245
  20. Bae EA, Park SY, Kim DH. Constitutive $\beta$-glucosidases hydrolyzing ginsenoside RbI and Rb2from humanintestinal bacteria. Biol Pharm Bull. 23: 1481-1485 (2000) https://doi.org/10.1248/bpb.23.1481
  21. Bae EA, Han MJ, Choo MK, Park SY, Kim DH. Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol harm Bull. 25: 58-63 (2002) https://doi.org/10.1248/bpb.25.58
  22. Lee SJ, Sung JR, Lee SJ, Moon CK, Lee BH. Antitumor activity of a novel ginsen gsaponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Cancer Lett. 144: 39-43 (1999) https://doi.org/10.1016/S0304-3835(99)00188-3
  23. Bae EA, Choo MK, Park EK, Park SY, Shin HY, Kim DH. Metabolism of ginsenoside Rc by human intestinal bacteria and its related antiallergic activity. Biol Pharm Bull. 25: 743-747 (2002) https://doi.org/10.1248/bpb.25.743
  24. Shin YW, Kim DH. Antipruritic effect of ginsenoside rb1 and compound k in scratching behavior mouse models. J Pharmacol Sci. 99: 83-88 (2005) https://doi.org/10.1254/jphs.FP0050260
  25. Shin YW, Bae EA, KimSS, Lee YC, Kim DH. Effectof ginsenoside RbI and compound K in chronic oxazoloneinduced mouse dermatitis. Int Immunopharmacol. 5: 1183-1191 (2005) https://doi.org/10.1016/j.intimp.2005.02.016
  26. Choo MK, Park EK, Han MJ, Kim DH. Antiallergic activity of ginseng and its ginsenosides. Planta Med. 69: 518-522 (2003) https://doi.org/10.1055/s-2003-40653
  27. Akagi M, Mio M, Miyoshi K, Tasaka K. Histamine release inhibition and prevention of the decrease in membrane fluidity induced by certain antiallergic drugs: analysis of the inhibitory mechanism of NCO-650. Immunopharmacol Immunotoxicol. 9: 257-7924 (1987) https://doi.org/10.3109/08923978709035214
  28. Ito H, Miyazaki T, Ono M, Sakurai H. Antiallergic activities of rabdosiin and its related compounds: chemical and biochemical evaluations. Bioorg MooChem. 6: 1051-1056 (1998) https://doi.org/10.1016/S0968-0896(98)00063-7
  29. Akao T, Kida H, KanaokaM, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 50: 1155-1160 (1998) https://doi.org/10.1111/j.2042-7158.1998.tb03327.x
  30. Kanaoka M, Akao T, Kobashi K. Appearance of compound K, a major metabolite of ginsenoside RbI by intestinal bacteria, in rat plasma after oral administration - measurement of compound K by enzyme immunoassay. Biol Pharm Bull. 21: 245-249 (1998) https://doi.org/10.1248/bpb.21.245
  31. Tawab MA, Bahr D, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in human after oral administration. Drug Metab Dispos. 31: 1065-1071 (2003) https://doi.org/10.1124/dmd.31.8.1065
  32. Azuma H, Nanno K, Yoshimura T. Pharmacological properties of N-(3',4'-dimethoxycinnamoyl) anthranilic acid (N5'), a new antiatopic agent. Br J Pharmacol. 58: 483-488 (1976) https://doi.org/10.1111/j.1476-5381.1976.tb08614.x

Cited by

  1. Anti-inflammatory and Anti-oxidative Effects of Korean Red Ginseng Extract in Human Keratinocytes vol.11, pp.1, 2011, https://doi.org/10.4110/in.2011.11.1.42
  2. Therapeutic Effects of Fermented Red Ginseng in Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Study vol.3, pp.2, 2011, https://doi.org/10.4168/aair.2011.3.2.103
  3. Effects of ginsenoside Re on LPS-induced inflammatory mediators in BV2 microglial cells vol.12, pp.1, 2012, https://doi.org/10.1186/1472-6882-12-196
  4. Modulation of nitrergic signalling pathway by American ginseng attenuates chronic unpredictable stress-induced cognitive impairment, neuroinflammation, and biochemical alterations vol.387, pp.2, 2014, https://doi.org/10.1007/s00210-013-0925-5
  5. Anti-Atopic Properties of Gracillin Isolated from Dioscorea quinqueloba on 2,4-Dinitrochlorobenzene-Induced Skin Lesions in Mice vol.10, pp.9, 2018, https://doi.org/10.3390/nu10091205
  6. The Beneficial Effect of Korean Red Ginseng Extract on Atopic Dermatitis Patients: An 8 Weeks Open, Noncomparative Clinical Study vol.30, pp.3, 2018, https://doi.org/10.5021/ad.2018.30.3.304